• Publications
  • Influence
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
This article discusses the prevention of venous thromboembolism (VTE) and is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
This article discusses the prevention of venous thromboembolism (VTE) and is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy:
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality.
The estimated total number of symptomatic VTE events (range based on probabilistic sensitivity analysis) per annum within the six EU countries was 465,715; almost three-quarters of all VTE-related deaths were from hospital-acquired VTE.
A prospective study of the incidence of deep‐vein thrombosis within a defined urban population
In a prospective study all positive phlebographies within the well‐defined population of the city of MalmÖ, Sweden, during 1987 were studied in order to determine the incidence of deep venous thrombosis (DVT), and risk factors were found to be in accordance with earlier studies.
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Enoxaparin prophylaxis for four weeks after surgery for abdominal or pelvic cancer is safe and significantly reduces the incidence of venographically demonstrated thrombosis, as compared with enoxapin prophyllaxis for one week.
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
A definition of major bleeding that should be applicable to all agents that interfere with hemostasis is developed and is to seek approval from the regulatory authorities to enhance its incorporation into future clinical trial protocols.
Heparin-Induced Thrombocytopenia
The treatment consists in discontinuing heparin administration and in setting up an alternative treatment for which two drugs are indicated in France: Orgaran and Refludan.
Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies.
PVT was found to be more common than indicated by previous clinical series and the markedly excess risk in cirrhosis and hepatic carcinoma should warrant an increased awareness in patients for whom prospective studies of directed intervention might be considered.
Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.
There were significantly fewer venous thromboembolic complications in patients undergoing elective hip replacement when prophylaxis with enoxaparin was given for a total of one month, rather than only during the hospitalization.
Incidence of venous thromboembolism verified by necropsy over 30 years.
The overall incidence of venous thromboembolism has not changed over 30 years, and the proportion of the population aged over 65 has doubled, and this may have masked the beneficial effects of prophylaxis and early mobilisation.